Alhadrami, H. A., Sayed, A. M., Al-Khatabi, H., Alhakamy, N. A., & Rateb, M. E. (2021). Scaffold Hopping of α-Rubromycin Enables Direct Access to FDA-Approved Cromoglicic Acid as a SARS-CoV-2 M(Pro) Inhibitor. Pharmaceuticals (Basel).

Alhadrami, Hani A., Ahmed M. Sayed, Heba Al-Khatabi, Nabil A. Alhakamy, a Mostafa E. Rateb. "Scaffold Hopping of α-Rubromycin Enables Direct Access to FDA-Approved Cromoglicic Acid As a SARS-CoV-2 M(Pro) Inhibitor." Pharmaceuticals (Basel) 2021.

Alhadrami, Hani A., et al. "Scaffold Hopping of α-Rubromycin Enables Direct Access to FDA-Approved Cromoglicic Acid As a SARS-CoV-2 M(Pro) Inhibitor." Pharmaceuticals (Basel) 2021.